Background: Prognostic biomarkers for osteosarcoma (OS) at the time of diagnosis are lacking.
INTRODUCTION
Response to preoperative chemotherapy is the only validated prognostic marker that identifies osteosarcoma (OS) patients at high risk for relapse and metastasis. 1 Because OS patients cannot be stratified at the time of diagnosis, all pediatric and adolescent OS patients receive combination chemotherapy with cisplatin, doxorubicin, and high-dose methotrexate followed by surgical excision of the primary tumor. Neither the administration of high-dose ifosfamide with or without etoposide to patients with poor chemotherapy responses Abbreviations: Hes, hairy/enhancer of split; OS, osteosarcoma; RANKL, receptor activator of nuclear factor-B ligand (defined as <90% tumor necrosis) nor the administration of interferon alpha-2b to patients with good chemotherapy response (>90% tumor necrosis) has improved OS patients' survival. 2, 3 It is yet to be determined, however, whether adding these agents to the preoperative chemotherapeutic regimen will improve disease response and survival for either prognosis group. A predictive biomarker assessed at the time of diagnosis is needed to meet this need. Understanding the pathways that control OS development may identify new prognostic and predictive biomarkers for OS.
Although cure rates in patients with localized OS are as high as 60-70%, patients who have metastatic relapse have 5-year overall survival rates of only 15-20%. 4 Currently, there is no predictive marker at initial diagnosis to identify which patients are at high risk for Pediatr Blood Cancer 2017; 64: e26318 c 2016 Wiley Periodicals, Inc. 1 of 8 wileyonlinelibrary.com/journal/pbc developing metastatic disease. The metastatic behavior of some cancers is linked to differentiation status: the more immature the cell population is, the higher is the likelihood for metastasis. 5, 6 OS is a highly heterogeneous mixture of cells representing the full spectrum of differentiation from highly proliferative mesenchymal stem cells to terminally differentiated slowly proliferating bone/osteoid-forming osteoblasts. 7 Normal bone development is tightly regulated by a multistep differentiation pathway in which various transcription factors control the progression of mesenchymal stem cells from an immature stem-like state through osteogenic lineage commitment to terminal differentiation. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Because disruption of osteogenic differentiation is thought to lead to the development and progression of OS, 11, 19 we sought to expand our understanding of the underlying molecular mechanisms that drive tumor cell differentiation.
The Notch signaling pathway is a mediator of cell differentiation that is critical for normal bone development. Notch signaling is activated when a membrane-bound ligand (Jag1, Jag2, Dll1, Dll3, or Dll4) on a signal-sending cell physically interacts with the extracellular domain of a membrane-bound Notch receptor (Notch1-4) on a signal-receiving cell. This interaction results in the two-step cleavage of the intracellular domain of Notch receptors. Once cleaved, the intracellular domain translocates to the nucleus to promote the expression of a number of target genes. These "Notch effectors" include hairy/enhancer of split 1-7 (Hes1-7), Hey1-2, and deltex.
Notch receptor knockout results in severe skeletal abnormalities in mice, [20] [21] [22] suggesting a critical role for Notch signaling in bone development. Additionally, activation of the Notch pathway promotes the differentiation of osteoblasts from mesenchymal stem cells while inhibiting the development of osteoclasts. 23 Finally, the Notch downstream target Hes4 regulates the lineage commitment of normal bone marrow stromal cells to the osteogenic pathway 24 and is a biomarker that identifies solid tumors likely to respond to -secretase inhibitor-based therapies. [25] [26] [27] The role of Hes4 in the development and progression of OS has yet to be defined, however.
The purpose of this study is to identify clinically relevant biomarkers that allow for the stratification of patients into good or poor responders to chemotherapy at diagnosis. We also aim to understand the biology of these markers in OS pathogenesis. We demonstrate here that high Hes4 expression promotes an immature, progenitor-like phenotype in OS cells, increasing the cell's invasive capacity. High expression of Hes4 is correlated with more aggressive and metastatic OS tumors in mice and with poor metastasis-free and overall survival in patients. Our data suggest that high Hes4 is important biologically in OS pathogenesis and has potential as a clinically relevant prognostic biomarker in the stratification of patients into good or poor responders to chemotherapy at diagnosis.
METHODS

Patient survival and metastasis probability
The R2: Genomics Analysis and Visualization Platform (Academic Medical Center, Amsterdam, the Netherlands; http://r2.amc.nl) was used to generate Kaplan-Meier overall survival curves using the "Mixed Osteosarcoma-Kuijjer-127-vst-ilmnhwg6v2" data set. 28 Genome-wide gene expression analysis was performed on 84 pretreatment high-grade OS diagnostic biopsies, of which 29 overlapped with the 32 samples used for copy number analysis. Two different sets of control samples were used for comparison: osteoblasts (n = 3) and mesenchymal stem cells (n = 12, GEO accession number GSE28974).
Pretreatment biopsies of high-grade primary tumors from OS patient samples were analyzed on the basis of high versus low Hes1 or Hes4.
The R2 generated "scan" cut-off modus was used to determine the threshold point that most significantly separates high relative gene expression versus low relative gene expression.
Cell culture
The human fetal osteoblastic cell line hFOB (American Type Culture Collection) was cultured at 34°C with 5% CO 2 
Retroviral transduction of Hes4
Green fluorescent protein (GFP) containing retroviral MigR1 constructs with and without Hes1 or Hes4 (MigR1-GFP, MigR1-GFP-Hes1, and MigR1-GFP-Hes4) were used to make a replication-incompetent retrovirus that was then used to infect HOS and CCHD cells as described previously. 29 
Proliferation of OS cells that overexpress GFP, GFP-Hes1, or Hes4
HOS and CCHD cells were transduced with MigR1-GFP, MigR1-GFPHes1, or MigR1-GFP-Hes4 and seeded in six-well plates in triplicate. 
Quantification of RNA in OS cells
Reverse transcription-quantitative PCR (RT-qPCR) was used to quantify changes in the expression of markers of mesenchymal stem cells (Nanog, Sox2, and Oct4), osteoprogenitors/preosteoblasts (RunX2 and osterix), early osteoblasts (alkaline phosphatase), and mature osteoblasts and osteocytes (osteocalcin and osteopontin).
After transduction with MigR1-GFP or MigR1-GFP-Hes4, HOS and CCHD cells were sorted for GFP, and RNA was extracted using the RNeasy Mini Kit (Qiagen). cDNA was constructed using the Omnis- 
In vivo mouse xenografts
All animal experiments were approved by the MD Anderson Institutional Animal Care and Use Committee. 
Intratibial injection of OS cells
Immunohistochemical quantification of metastases
Representative images of lung tumor burdens in the mice were obtained using a cooled charge-coupled device C5810 camera (Hama- 
Quantification of Lysis
In order to determine the extent of lysis in the bone as a result of OS tumor burden, we used a previously developed radiographic grading scheme. 30 Briefly, radiographs of the tibia were taken on the day the experiment was terminated (week 6) using the In Vivo Xtreme (Bruker).
A grading system using numerical values from 0 to 4 was used to quantify the extent of bone destruction, where a grade of 0 represents no lysis, a grade of 1 represents minimal bone destruction in the medullary canal, 2 is moderate bone lysis within the medullary cortex with minimal destruction to the cortex, 3 is severe bone lysis with cortical disruption, and 4 is massive destruction with soft tissue extension of the tumor.
Statistical Analysis
The significance of all experimental treatments was assessed using the Student's t-test with an alpha error threshold of 0.05. All experiments were conducted at least three times unless stated otherwise.
RESULTS
Hes4 expression correlates with poor survival and high metastasis incidence in OS patients
Notch signaling has been shown to regulate metastasis in several types of cancer. [31] [32] [33] [34] [35] [36] To determine whether expression of Notch downstream targets correlates with metastasis-free and overall survival in patients with OS, we used a preexisting RNA microarray database to examine gene expression within pretreatment highgrade OS primary patient tumor biopsies. High and low expression is defined by computer-generated thresholds that promote the greatest F I G U R E 1 High Hes4 expression in pretreatment of high-grade OS tumor biopsies correlates with decreased metastasis-free and overall survival outcomes. The R2: Genomics Analysis and Visualization Platform was used to generate Kaplan-Meier metastasis-free and overall survival curves using the Mixed Osteosarcoma-Kuijjer-127-vst-ilmnhwg6v2 data set. Genome-wide gene expression analysis was performed using 84 pretreatment high-grade diagnostic OS biopsy samples. Two different sets of control samples were used for comparison: osteoblasts (n = 3) and mesenchymal stem cells (n = 12; GEO accession number GSE28974). High Hes4 expression was correlated with significantly lower probabilities of both overall and metastasisfree survival than low Hes4 expression (overall survival, P < 0.01; metastasis-free survival, P < 0.05) distinction between gene expression populations. High Hes4 expression, observed in 30 of 69 (43%) OS patients, correlated with significantly decreased metastasis-free and overall survival outcomes (Fig. 1) . In contrast, the expression of Hes1, Hes2, Hes5, Hey1, Hey2, and DTX was not prognostically significant ( Supplementary Fig. S1 ).
Hes4 overexpression increases OS invasion
To and Supplementary Fig. S2E ). To determine whether this effect on invasion and proliferation was induced by other Notch effectors as well, we transduced HOS and CCHD cells with GFP-Hes1. In contrast with Hes4, overexpression of Hes1 decreased both invasion and proliferation ( Supplementary Fig. S3 ). These data indicate that the phenotypic characteristics of OS may depend on which specific Notch downstream target gene is activated. We focused on Hes4 because of the correlation between Hes4 expression and decreased OS patients' survival.
Terminal differentiation is inhibited in Hes4-overexpressing OS cells
Overexpression of Hes4 is correlated with an aggressive phenotype, as defined by increased invasive capacity. An aggressive phenotype has or HOS-GFP-Hes4 OS cells. HOS-GFP cells generated numerous calcium nodules, which appeared as red punctate points (Fig. 3) . In addition to dark red focal points of thick calcium buildup, a calcium sheet appeared as a smooth bright red surface within the staining. In the presence of differentiation media, HOS-GFP-Hes4 OS cells produced fewer calcium nodules than did HOS-GFP control cells (mean ± SEM:
HOS-GFP, 175.3 ± 34.9; HOS-GFP-Hes4, 13.3 ± 3.5; Fig. 3 ) and almost no calcium sheets. This suggested that Hes4 overexpression prevented calcium deposition, which is indicative of an immature, poorly differentiated phenotype.
Hes4-overexpressing OS cells express increased levels of markers of committed osteoprogenitors and decreased levels of a marker of preosteoblasts
The multistep progression of mesenchymal stem cells to terminally differentiated osteoblasts is delineated by the presence or absence of well-defined transcription factors ( Supplementary Fig. S4 ). To determine the stage at which Hes4 blocked OS differentiation, we used RT-qPCR to quantify markers of committed osteoprogenitors and preosteoblasts (RunX2 and osterix) and early osteoblasts (alkaline phosphatase). In both HOS and CCHD cells, overexpression of Hes4 RT-qPCR for RunX2, osterix, and alkaline phosphatase expression (as indicated) was normalized according to GAPDH expression relative to that in GFP-transduced control cells. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. Bars, mean ± SEM (n = 3). (B) Even during forced differentiation, Hes4 prevents increased alkaline phosphatase expression. RNA harvested from CCHD and HOS cells 10-15 days after transduction with GFP or GFP-Hes4 and after 3-9 days of incubation with differentiation media. RT-qPCR was performed for alkaline phosphatase expression and normalized according to GAPDH expression relative to that in GFP-transduced control cells. **P ≤ 0.01. Bars, mean ± SEM (n = 3) resulted in increased expression of RunX2 and osterix, but decreased alkaline phosphatase, compared to GFP control cells. Taken together, these data suggest that there is a block in the progression of committed progenitors to early osteoblasts (Fig. 4A) . We found that in the presence of differentiation media, it takes 9 days and 21 days for differentiation to occur in CCHD and HOS cell, respectively. To determine whether the expression of Hes4 blocked the maturation of osteogenic progenitors, control GFP and GFP-Hes4-overexpressing CCHD and HOS cells were incubated in differentiation media for 3 or 9 days, respectively (a time point in the middle of the differentiation process).
The cells were then evaluated for alkaline phosphatase expression.
Even in the differentiation media, Hes4 blocked OS cell differentiation (Fig. 4B) .
Effect of Hes4 overexpression on OS tumor growth and metastasis in vivo
Our data indicated that Hes4-overexpressing OS cells are less differ- weeks postinjection (Fig. 5C ).
High RunX2 and osterix expression correlate with decreased metastasis-free and overall survival in OS patients
We in pretreatment high-grade OS primary tumor biopsies was correlated with decreased metastasis-free survival (P = 0.017 and 0.007, respectively) and overall survival (P = 0.0004 and 0.0005, respectively) (Fig. 6 ).
DISCUSSION
For the first time, we describe the role of Hes4 in bone differentiation in OS. Importantly, our data suggest that expression of Hes4 may be a prognostic biomarker of patient outcome in newly diagnosed patients with high-grade OS. High expression of Hes4 is also correlated with decreased overall and metastasis-free patient survival. We found that overexpression of Hes4 in OS cells blocked terminal differentiation resulting in an immature preosteoblastic phenotype ( Supplementary   Fig. S5 ). When injected orthotopically, Hes4-overexpressing cells produced larger tumors with increased lytic and metastatic capacity.
Defects early in osteogenic cell differentiation are hypothesized to result in more aggressive OS tumors when compared to defects at later stages. 37 In the present study, we confirmed this link. We showed that high Hes4 expression is correlated with a less differentiated phenotype in vitro and an increase in metastatic potential in vivo. 
Expression of osteogenic commitment markers in human OS samples correlates with significantly decreased overall and metastasis-free survival outcomes. The R2: Genomics Analysis and Visualization Platform was used to generate KaplanMeier metastasis-free and overall survival curves using the Mixed Osteosarcoma-Kuijjer-127-vst-ilmnhwg6v2 data set. Genome-wide gene expression analysis was performed using 84 pretreatment high-grade diagnostic OS biopsy samples. Two different sets of control samples were used for comparison: osteoblasts (n = 3) and mesenchymal stem cells (n = 12; GEO accession number GSE28974). Patients with high RunX2 or osterix expression had significantly lower probabilities of both overall and metastasis-free survival than did those with low RunX2 or osterix expression. *P < 0.01; **P < 0.05 to RunX2 to prevent osteogenic differentiation. 24 When Hes4 is over- 
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